# A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients

> **NCT02671942** · PHASE2 · TERMINATED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 55 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Roflumilast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02671942
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03
- **Primary completion:** 2018-06-13
- **Final completion:** 2018-06-13
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2019-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02671942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02671942, "A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02671942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*